Antihistamine Safety Questions, Liability Risks Cautioned By Aventis
This article was originally published in The Tan Sheet
Executive Summary
A switch of Allegra to nonprescription status could create the potential for unknown consumer risks and open the door to costly lawsuits, Aventis Senior VP-Medical & Regulatory Affairs Francois Nader, MD, suggested to a joint FDA advisory panel.You may also be interested in...
FDA Commissioner Logjam Broken?: NDAC’s Wood May Be Nominee
FDA Commissioner Logjam Broken?: NDAC’s Wood May Be Nominee
FDA Commissioner Logjam Broken?: NDAC’s Wood May Be Nominee
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: